Rosellina Margherita Mancina

List of Publications by Year
in descending order

54 papers	3,924 citations	172457 29 h-index	161849 54 g-index
54 all docs	54 docs citations	54 times ranked	4567 citing authors

#	Article	IF	Citations
1	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology, 2016, 150, 1219-1230.e6.	1.3	506
2	An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans. Cell Metabolism, 2018, 27, 559-571.e5.	16.2	321
3	Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology, 2015, 63, 705-712.	3.7	309
4	PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Human Molecular Genetics, 2014, 23, 4077-4085.	2.9	293
5	Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. Journal of Hepatology, 2012, 57, 1276-1282.	3.7	232
6	PNPLA3 I148M polymorphism and progressive liver disease. World Journal of Gastroenterology, 2013, 19, 6969.	3.3	207
7	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Scientific Reports, 2017, 7, 4492.	3.3	193
8	Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 574-580.	2.4	153
9	Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Molecular Metabolism, 2019, 22, 49-61.	6.5	140
10	PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Digestive and Liver Disease, 2012, 44, 1037-1041.	0.9	100
11	The rs2294918 E434K variant modulates patatinâ€like phospholipase domainâ€containing 3 expression and liver damage. Hepatology, 2016, 63, 787-798.	7.3	93
12	PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. Human Molecular Genetics, 2016, 25, ddw341.	2.9	86
13	LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover. Gut, 2021, 70, 180-193.	12.1	86
14	The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. Scientific Reports, 2019, 9, 11585.	3.3	82
15	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. Gastroenterology, 2021, 160, 1634-1646.e7.	1.3	82
16	PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity ,. Journal of Nutrition, 2015, 145, 1687-1691.	2.9	78
17	Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut, 2020, 69, 1855-1866.	12.1	75
18	Paradoxical Dissociation Between Hepatic Fat Content and De Novo Lipogenesis Due to PNPLA3 Sequence Variant. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E821-E825.	3.6	64

#	Article	IF	Citations
19	Genetic diagnosis of familial hypercholesterolaemia by targeted nextâ€generation sequencing. Journal of Internal Medicine, 2014, 276, 396-403.	6.0	57
20	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 1001-1012.	3.7	54
21	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology, 2015, 62, 111-117.	7.3	52
22	MBOAT7 is anchored to endomembranes by six transmembrane domains. Journal of Structural Biology, 2019, 206, 349-360.	2.8	48
23	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancer Medicine, 2017, 6, 1930-1940.	2.8	43
24	PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. Journal of Lipid Research, 2019, 60, 1144-1153.	4.2	42
25	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. Hepatology Communications, 2018, 2, 666-675.	4.3	38
26	Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. JCI Insight, 2020, 5, .	5.0	38
27	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. Journal of Hepatology, 2022, 77, 596-606.	3.7	38
28	Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning. European Journal of Preventive Cardiology, 2020, 27, 1639-1646.	1.8	37
29	DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology, 2016, 63, 418-427.	7.3	31
30	Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia. Journal of Clinical Lipidology, 2016, 10, 816-823.	1.5	31
31	Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2023, 21, 1523-1532.e1.	4.4	31
32	Gastrointestinal Symptoms of and Psychosocial Changes in Inflammatory Bowel Disease: A Nursing-Led Cross-Sectional Study of Patients in Clinical Remission. Medicina (Lithuania), 2020, 56, 45.	2.0	28
33	PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes. Inflammatory Bowel Diseases, 2016, 22, 134-140.	1.9	27
34	PCSK9 rs11591147 R46L lossâ€ofâ€function variant protects against liver damage in individuals with NAFLD. Liver International, 2021, 41, 321-332.	3.9	26
35	Deregulation of SGK1 in Ulcerative Colitis: A Paradoxical Relationship Between Immune Cells and Colonic Epithelial Cells. Inflammatory Bowel Diseases, 2018, 24, 1967-1977.	1.9	23
36	Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels. Journal of Clinical Lipidology, 2019, 13, 778-787.e6.	1.5	21

#	Article	IF	Citations
37	The COBLL1 C allele is associated with lower serum insulin levels and lower insulin resistance in overweight and obese children. Diabetes/Metabolism Research and Reviews, 2013, 29, 413-416.	4.0	19
38	Transmembrane-6 superfamily member 2 (TM6SF2) E167K variant increases susceptibility to hepatic steatosis in obese children. Digestive and Liver Disease, 2016, 48, 100-101.	0.9	18
39	High prevalence of genetic determined familial hypercholesterolemia in premature coronary artery disease . The Application of Clinical Genetics, 2019, Volume 12, 71-78.	3.0	15
40	PSD3 downregulation confers protection against fatty liver disease. Nature Metabolism, 2022, 4, 60-75.	11.9	15
41	Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery. Liver International, 2022, 42, 374-383.	3.9	14
42	A two gene-based risk score predicts alcoholic cirrhosis development in males with at-risk alcohol consumption. The Application of Clinical Genetics, 2019, Volume 12, 1-10.	3.0	13
43	Molecular analysis of three known and one novel LPL variants in patients with type I hyperlipoproteinemia. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 158-164.	2.6	12
44	Ulcerative Colitis as an Independent Risk Factor for Hepatic Steatosis. Gastroenterology Nursing, 2020, 43, 292-297.	0.4	11
45	Genetic Susceptibility to Chronic Liver Disease in Individuals from Pakistan. International Journal of Molecular Sciences, 2020, 21, 3558.	4.1	8
46	TheIRS1rs2943641 Variant and Risk of Future Cancer Among Morbidly Obese Individuals. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E785-E789.	3.6	7
47	Effects of listening to music in digestive endoscopy: A prospective intervention study led by nursing. Journal of Advanced Nursing, 2020, 76, 2993-3002.	3.3	5
48	Genetic variants in the MTHFR are not associated with fatty liver disease. Liver International, 2020, 40, 1934-1940.	3.9	5
49	Effects of PNPLA3 I148M on hepatic lipid and veryâ€lowâ€density lipoprotein metabolism in humans. Journal of Internal Medicine, 2022, 291, 218-223.	6.0	5
50	Four-Week Omega-3 Supplementation in Carriers of the Prosteatotic <i>PNPLA3</i> p.I148M Genetic Variant: An Open-Label Study. Lifestyle Genomics, 2019, 12, 10-17.	1.7	4
51	Natural Extracts as Modifiers of Intracellular Lipid Handling. Annals of Hepatology, 2018, 17, 180-181.	1.5	2
52	Cross talk between liver and adipose tissue: A new role for PNPLA3?. Liver International, 2020, 40, 2074-2075.	3.9	2
53	Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches. International Journal of Molecular Sciences, 2022, 23, 1617.	4.1	2
54	Satisfaction with Social Roles and Physical Function in Immune-mediated Inflammatory Diseases: A Cross-Sectional Study. Reviews on Recent Clinical Trials, 2022, 17, 177-186.	0.8	2